Safety and efficacy of cetuximab-chemotherapy combination in Saudi patients with metastatic colorectal cancer

Indian Journal of Cancer

Volumn 44, Issue 2, 2007, Pages 56-61

  Ibrahim, Ezzeldin M ^a   Zeeneldin, Ahmed A ^a   Al Gahmi, Aboelkhair M ^a   Sallam, Yasser A ^a   Fawzi, Ehab E ^a   Bahadur, Yasser A ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Cetuximab; Chemotherapy; Metastatic colorectal carcinoma; Saudi Arabia

Indexed keywords

EID: 35448952240     PISSN: 0019509X     EISSN: None     Source Type: Journal    
DOI: 10.4103/0019-509X.35812     Document Type: Article

References (24)

1. Saudi National Cancer Registry. Cancer Incidence Report, 2002. Available from: http://www.kfshrc.edu.sa/NCR/.
2. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209-14.
3. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47.
4. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomized trial. Lancet 2000;355:1041-7.
5. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
6. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004;22:229-37.
7. Kohne CH, van Cutsem E, Wils J, Bokemeyer C, El-Serafi M, Lutz MP, et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol 2005;23:4856-65.
8. Venook A. Critical evaluation of current treatments in metastatic colorectal cancer. Oncologist 2005;10:250-61.
9. Saltz B, Rubin M, Hochster H, Tchekmeydian S, Waksa HI, Needle N, et al. Cetuximab (IMC-C22 plus irinotecan (CPT-1 is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001;20:2a.
10. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45.
11. Jaffe CC. Measures of response: RECIST, WHO and new alternatives. J Clin Oncol 2006;24:3245-51.
12. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
13. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). 2006 August 9. [Last cited on 2006 Sep 1]; v3. Available from: http://ctep.cancer.gov/forms/ CTCAEv3.pdf.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
15. Cox DR. The Analysis of Binary Data. London, UK: Methuen; 1970.
16. Dei Tos AP. The biology of epidermal growth factor receptor and its value as a prognostic/predictive factor. Int J Biol Markers 2007;22:S3-9.
17. Pfeiffer P, Qvortrup C, Eriksen JG. Current role of antibody therapy in patients with metastatic colorectal cancer. Oncogene 2007;26:3661-78.
18. Galizia G, Lieto E, De Vita F, Orditura M, Castellano P, Troiani T, et al. Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer. Oncogene 2007;26:3654-60.
19. Vincenzi B, Santini D, Rabitti C, Coppola R, Beomonte Zobel B, Tradella L, et al. Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: A single centre phase Il trial. Br J Cancer 2006;94:792-7.
20. Rougier P, Raoul JL, Van Laethem J. Cetuximab+FOLFIRI as first-line treatment for metastatic colorectal CA. Proc Am Soc Clin Oncol 2004.
21. Tabernero J, Van Cutsem E, Sastre J. An international phase Il study of cetuximab in combination with oxaliplatin/5-fluorouracil -FU)/ folinic acid (FA) (FOLFOX- in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR): Preliminary results. Proc Am Soc Clin Oncol.
22. Folprecht G, Lutz MP, Schoffski P, Seufferlein T, Nolting A, Poliert P, et al. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 2006;17:450-6.
23. Venook A. Protocol chair: Phase III randomized study of cetuximab and/or bevacizumab in combination with either oxaliplatin, fluorouracil and leucovorin calcium (FOLFOX) or irinotecan hydrochloride, fluorouracil and leucovorin calcium (FOLFIRI) in patients with previously untreated metastatic adenocarcinoma of the colon or rectum: Protocol ID: CALGB-C80405. Last modified: 8/24/2006. National Cancer Institute: Clinical Trials (database); 2006.
24. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78.